What Was Ozempic Originally For? The Type 2 Diabetes Drug That Became a Weight-Loss Phenomenon

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic received FDA approval in December 2017 exclusively for treating type 2 diabetes in adults, not weight loss
• The same active ingredient (semaglutide) was later approved as Wegovy in June 2021 specifically for chronic weight management at a higher dose
• Ozempic's weight-loss effects were documented in diabetes trials but were considered a secondary benefit, not the primary therapeutic target
• The off-label use of Ozempic for weight loss created a supply crisis that affected diabetes patients who needed the medication for its original FDA-approved purpose

Direct answer (40-60 words)

Ozempic was originally approved by the FDA in December 2017 as a once-weekly injectable medication to improve blood sugar control in adults with type 2 diabetes. Weight loss was observed in clinical trials but was a secondary effect. The same drug (semaglutide) was later reformulated and approved as Wegovy in 2021 specifically for weight management.

Table of contents

1. The FDA approval timeline: diabetes first, weight loss second
2. What type 2 diabetes is and why semaglutide works for it
3. The clinical trials that led to Ozempic's diabetes approval
4. When the weight-loss signal became impossible to ignore
5. The dose difference between diabetes and weight-loss formulations
6. What most articles get wrong about "original purpose"
7. The off-label prescription pattern that changed everything
8. Why the same molecule got two different brand names
9. The supply crisis and who it hurt most
10. The FormBlends clinical pattern: diabetes vs weight-loss patient profiles
11. When off-label use is appropriate and when it is not
12. FAQ
13. Sources

The FDA approval timeline: diabetes first, weight loss second

The chronology matters because it explains the current regulatory and supply landscape:

December 5, 2017: The FDA approves Ozempic (semaglutide injection) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The approved doses are 0.5 mg and 1 mg once weekly. The label includes a cardiovascular benefit claim based on the SUSTAIN-6 trial showing reduced risk of major adverse cardiovascular events.

January 2020: The FDA approves a higher 2 mg dose of Ozempic for type 2 diabetes based on the SUSTAIN-FORTE trial, which showed superior A1C reduction compared to the 1 mg dose.

June 4, 2021: The FDA approves Wegovy (semaglutide injection) at a 2.4 mg once-weekly dose specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. This is a separate drug application with different labeling, different dosing, and different pen devices.

2022-2023: Widespread off-label prescribing of Ozempic for weight loss creates supply shortages. Novo Nordisk prioritizes Ozempic manufacturing for diabetes patients. The FDA adds Ozempic to the drug shortage list multiple times.

March 2024: The FDA approves Wegovy for reducing cardiovascular risk in adults with established cardiovascular disease and obesity, expanding its indication beyond weight management alone (SELECT trial data).

The timeline shows a clear sequence: diabetes treatment came first, weight-loss approval came four years later as a separate product, and the off-label crossover happened in between.

What type 2 diabetes is and why semaglutide works for it

Type 2 diabetes is a metabolic disorder where the body becomes resistant to insulin and the pancreas cannot produce enough insulin to overcome that resistance. Blood glucose rises above normal levels (fasting glucose ≥126 mg/dL or A1C ≥6.5%), which over years damages blood vessels, nerves, kidneys, eyes, and the cardiovascular system.

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA). It mimics a natural hormone called GLP-1 that your intestines release after eating. GLP-1 does three things that lower blood sugar:

1. Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner. When blood sugar is high, semaglutide tells the pancreas to release more insulin. When blood sugar is normal or low, it does not, which reduces hypoglycemia risk compared to older diabetes drugs like sulfonylureas.

1. Suppresses glucagon secretion from pancreatic alpha cells. Glucagon tells the liver to release stored glucose. Suppressing glucagon means less glucose enters the bloodstream from liver stores.

1. Slows gastric emptying. Food moves more slowly from the stomach to the intestines, which smooths out post-meal glucose spikes.

The result is lower A1C (a measure of average blood sugar over 3 months), lower fasting glucose, and lower post-meal glucose. The SUSTAIN clinical trial program showed A1C reductions of 1.5% to 1.8% from baseline, which is clinically significant. For context, metformin (the most common first-line diabetes drug) typically reduces A1C by 1% to 1.5%.

The weight loss that happens on semaglutide is partly a side effect of slower gastric emptying (you feel full longer) and partly a direct effect on appetite centers in the brain. GLP-1 receptors exist in the hypothalamus and brainstem, areas that regulate hunger and satiety. Activating those receptors reduces appetite independent of the gastric effects.

For diabetes treatment, the weight loss was considered a bonus. Most type 2 diabetes patients are overweight or obese, and weight loss improves insulin sensitivity, which makes blood sugar easier to control. But the FDA approval was based on glucose control, not weight endpoints.

The clinical trials that led to Ozempic's diabetes approval

The SUSTAIN trial program (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) consisted of 10 phase 3 trials enrolling over 8,000 patients with type 2 diabetes. The trials compared semaglutide to placebo, other GLP-1 agonists, and other diabetes drug classes.

Key trials:

Trial	Comparator	N	A1C reduction (semaglutide 1 mg)	Weight loss (semaglutide 1 mg)
SUSTAIN-1	Placebo	388	-1.5%	-4.5 kg
SUSTAIN-2	Sitagliptin 100 mg	1,231	-1.3%	-4.3 kg
SUSTAIN-3	Exenatide ER 2 mg	809	-1.5%	-5.6 kg
SUSTAIN-6 (cardiovascular outcomes)	Placebo	3,297	-1.1%	-4.9 kg
SUSTAIN-7	Dulaglutide 1.5 mg	1,201	-1.8%	-6.5 kg

SUSTAIN-6 was the cardiovascular outcomes trial that allowed Novo Nordisk to add a cardiovascular benefit claim to the Ozempic label. The trial showed a 26% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) compared to placebo over 2 years (Marso et al., New England Journal of Medicine, 2016).

The weight-loss numbers in these trials were consistent but secondary endpoints. The primary endpoint in every SUSTAIN trial was change in A1C from baseline. Weight was a secondary or exploratory endpoint. The FDA approval was granted based on glucose control efficacy and cardiovascular safety, not weight management.

The trial population was adults with type 2 diabetes, most of whom were overweight or obese at baseline. The average baseline BMI across SUSTAIN trials was 32 to 33 kg/m². Patients lost 4 to 6 kg (9 to 13 pounds) on average over 30 to 56 weeks, which is meaningful but modest compared to the weight loss seen in dedicated obesity trials.

When the weight-loss signal became impossible to ignore

The weight-loss signal was present from the earliest semaglutide trials, but three things made it impossible to ignore by 2019:

1. The dose-response relationship was clear. Higher semaglutide doses produced more weight loss. In SUSTAIN-FORTE (Frías et al., Diabetes Care, 2021), the 2 mg dose produced 6.9 kg of weight loss vs 6.0 kg at 1 mg. The signal suggested that even higher doses might produce clinically significant weight loss in non-diabetic patients.

2. The STEP trial program started enrolling. Novo Nordisk launched the Semaglutide Treatment Effect in People with Obesity (STEP) trials in 2018, testing semaglutide 2.4 mg once weekly in patients without diabetes. STEP-1 enrolled 1,961 adults with obesity or overweight and showed 14.9% mean weight loss over 68 weeks (Wilding et al., New England Journal of Medicine, 2021). That level of weight loss had never been seen with a non-surgical intervention in a large randomized trial.

3. Endocrinologists started prescribing Ozempic off-label. Between 2018 and 2020, before Wegovy was approved, endocrinologists and obesity medicine specialists began prescribing Ozempic off-label for weight management in patients who did not have diabetes. The practice was legal (off-label prescribing is permitted in the U.S.) and became common enough that Novo Nordisk faced a decision: either allow off-label use to continue or develop a separate weight-management product with dedicated trials and labeling.

They chose the latter. The STEP trials were designed to support a separate FDA application for obesity, which became Wegovy.

The weight-loss signal was always there, but the regulatory and commercial path required proving efficacy in a non-diabetic population with weight loss as the primary endpoint, not a secondary benefit.

The dose difference between diabetes and weight-loss formulations

The dose difference is the clearest marker that these are distinct therapeutic applications:

Ozempic (for type 2 diabetes):

• Starting dose: 0.25 mg once weekly for 4 weeks (not a therapeutic dose, just for tolerability)
• Maintenance doses: 0.5 mg, 1 mg, or 2 mg once weekly
• Most patients maintain on 0.5 mg or 1 mg
• The 2 mg dose is reserved for patients who need additional A1C reduction

Wegovy (for weight management):

• Starting dose: 0.25 mg once weekly for 4 weeks
• Escalation: 0.5 mg (weeks 5-8), 1 mg (weeks 9-12), 1.7 mg (weeks 13-16)
• Maintenance dose: 2.4 mg once weekly
• The 2.4 mg dose is the target for all patients unless side effects require staying at a lower dose

The 2.4 mg Wegovy dose is 2.4 times higher than the most common Ozempic maintenance dose (1 mg) and 20% higher than the maximum approved Ozempic dose (2 mg). The dose difference reflects different therapeutic goals: glucose control requires less GLP-1 receptor activation than sustained appetite suppression.

The STEP-2 trial (Davies et al., Lancet, 2021) directly tested this in patients with both diabetes and obesity. Participants were randomized to semaglutide 1 mg, semaglutide 2.4 mg, or placebo. The 2.4 mg dose produced 9.6% weight loss vs 7.0% at 1 mg. Both doses improved A1C similarly (about 1.6% reduction), but weight loss was dose-dependent.

The implication: if your goal is weight management, the Ozempic doses approved for diabetes are suboptimal. If your goal is glucose control, the Wegovy dose is higher than necessary and increases side-effect risk without additional glycemic benefit.

What most articles get wrong about "original purpose"

The common error is conflating "original FDA approval" with "original research intent." Most articles say "Ozempic was originally for diabetes" and stop there, implying the weight-loss effect was accidental or discovered post-approval.

That is not accurate. Novo Nordisk knew semaglutide caused weight loss before the first SUSTAIN trial enrolled. Earlier GLP-1 agonists (exenatide, liraglutide) had already shown weight-loss effects in diabetes trials. Liraglutide was approved as Saxenda for weight management in 2014, three years before Ozempic's diabetes approval.

The weight-loss effect was not a surprise. What was strategic was the regulatory pathway. Novo Nordisk pursued diabetes approval first for three reasons:

1. Faster path to market. The diabetes regulatory pathway was well-established. GLP-1 agonists were an accepted drug class. Approval timelines were predictable.

1. Larger initial market. In 2017, there were 30 million Americans with type 2 diabetes vs 15 million with obesity seeking pharmacotherapy. The diabetes market was larger and better-reimbursed by insurance.

1. Cardiovascular data strengthened both indications. SUSTAIN-6 showed cardiovascular benefit, which is valuable for both diabetes and obesity patients. Running the CV outcomes trial in diabetes patients made regulatory and ethical sense (diabetes patients have higher baseline CV risk).

The weight-management indication was always part of the long-term plan. The STEP trials were designed in parallel with late-stage SUSTAIN trials. Wegovy was not an afterthought. It was a planned second indication with a separate brand name, separate dosing, and separate marketing to avoid confusion and ensure appropriate use.

The error most articles make is treating the timeline as evidence of intent. The FDA approval timeline does not reflect research intent. It reflects regulatory strategy.

The off-label prescription pattern that changed everything

Between 2018 and 2021, a pattern emerged that Novo Nordisk did not anticipate at scale: primary care physicians and medical spas began prescribing Ozempic off-label for weight loss in patients without diabetes.

The pattern had three drivers:

1. Insurance coverage. Many insurers covered Ozempic for diabetes but did not cover weight-loss medications. Patients and prescribers discovered that an Ozempic prescription for "pre-diabetes" or "metabolic syndrome" would get approved, while a Saxenda or (later) Wegovy prescription would be denied.

1. Supply availability. Ozempic was widely available at pharmacies in 2019-2020. Saxenda required prior authorization and was frequently out of stock.

1. Dose flexibility. Ozempic pens allowed prescribers to customize doses. Some providers prescribed Ozempic and instructed patients to escalate to 2 mg or even split doses to approximate the 2.4 mg Wegovy dose.

The off-label use accelerated in late 2021 after Wegovy launched but immediately went on backorder due to manufacturing constraints. Prescribers who wanted to start patients on semaglutide for weight loss had no choice but to prescribe Ozempic off-label.

By mid-2022, an estimated 40% of Ozempic prescriptions were for off-label weight-loss use (Iqvia prescription data analysis). The off-label demand created a supply crisis. Pharmacies ran out of Ozempic. Patients with diabetes who had been stable on Ozempic for years could not refill their prescriptions.

The FDA added Ozempic to the drug shortage list in March 2022. Novo Nordisk issued statements asking prescribers to reserve Ozempic for diabetes patients and use Wegovy for weight management, but Wegovy remained on backorder through most of 2023.

The off-label pattern created a moral and logistical problem: a drug approved for one condition (diabetes) was being diverted to treat another condition (obesity), and the patients with the FDA-approved indication were the ones who suffered supply interruptions.

Why the same molecule got two different brand names

Novo Nordisk's decision to brand semaglutide as two separate products (Ozempic and Wegovy) rather than one product with two indications was deliberate and follows a pattern seen with other drugs.

Precedent: Liraglutide, an earlier GLP-1 agonist from Novo Nordisk, is branded as Victoza (for type 2 diabetes, 1.8 mg max dose) and Saxenda (for weight management, 3 mg dose). Same molecule, different brand names, different dosing, different indications.

Reasons for separate branding:

1. Dosing clarity. Different maintenance doses (1 mg vs 2.4 mg) mean different pen devices, different titration schedules, and different patient instructions. Separate brands reduce prescribing errors.

1. Insurance and reimbursement. Diabetes medications and weight-loss medications are covered under different insurance benefit categories. Separate NDC (National Drug Code) numbers allow insurers to apply different coverage policies. Ozempic is widely covered as a diabetes medication. Wegovy is often excluded or requires prior authorization as a weight-loss drug.

1. Marketing and patient perception. Branding Ozempic as a diabetes drug and Wegovy as a weight-management drug allows targeted marketing. Diabetes patients are not confused by weight-loss advertising, and obesity patients are not deterred by diabetes-focused messaging.

1. Regulatory flexibility. Separate applications allow Novo Nordisk to pursue additional indications independently. Wegovy's March 2024 approval for cardiovascular risk reduction in obesity (based on the SELECT trial) did not require changing the Ozempic label.

The downside is confusion. Patients and prescribers often do not realize Ozempic and Wegovy are the same active ingredient. The separate branding obscures the fact that the main difference is dose, not mechanism.

The strategy worked commercially. Ozempic became the top-selling GLP-1 agonist for diabetes. Wegovy became the top-selling GLP-1 for weight management. But the strategy also enabled the off-label substitution pattern that created supply problems.

The supply crisis and who it hurt most

The 2022-2023 Ozempic and Wegovy supply crisis had three overlapping causes:

1. Manufacturing capacity. Novo Nordisk underestimated demand for both products. The company's fill-finish capacity (the final step where the drug is loaded into injection pens) became the bottleneck. Expanding that capacity required building new facilities, which takes 2 to 3 years.

1. Off-label Ozempic prescribing. The surge in off-label weight-loss prescriptions consumed supply intended for diabetes patients.

1. Wegovy backorder. Wegovy launched in June 2021 and went on backorder by December 2021. It remained unavailable or intermittently available through mid-2023. Prescribers substituted Ozempic, which worsened the Ozempic shortage.

Who was hurt:

Diabetes patients on stable Ozempic therapy faced the most harm. Patients who had been taking Ozempic for 2 to 4 years, with well-controlled A1C and no side effects, could not refill prescriptions. Many were forced to switch to other GLP-1 agonists (dulaglutide, exenatide) or revert to older diabetes medications (insulin, sulfonylureas) with worse side-effect profiles.

The American Diabetes Association issued a statement in August 2022 expressing concern that off-label use was compromising access for patients with the FDA-approved indication. The statement stopped short of calling for restrictions on off-label prescribing but urged prescribers to prioritize diabetes patients.

Patients seeking weight management were also affected. Wegovy was unavailable, Ozempic was in shortage, and patients turned to compounded semaglutide, which is not FDA-approved but became widely available from compounding pharmacies during the shortage.

The supply crisis exposed a structural problem: the FDA approves drugs for specific indications, but it does not control how drugs are prescribed post-approval. Off-label prescribing is legal and common, but when off-label demand exceeds on-label supply, the regulatory system has no mechanism to prioritize patients with the approved indication.

Novo Nordisk's response was to increase manufacturing capacity and to explicitly request that prescribers reserve Ozempic for diabetes. By late 2023, supply stabilized as new production lines came online and Wegovy became consistently available.

The FormBlends clinical pattern: diabetes vs weight-loss patient profiles

What we observe across several thousand compounded semaglutide and tirzepatide treatment journeys is a clear bimodal patient profile that maps to the original vs expanded use cases:

Profile 1: Diabetes-primary patients (approximately 35% of compounded GLP-1 patients in our network)

• A1C at baseline: 7.5% to 9.5%
• BMI at baseline: 28 to 35
• Primary goal: glucose control
• Secondary goal: weight loss to improve insulin sensitivity
• Typical maintenance dose: semaglutide 0.5 to 1 mg weekly, or tirzepatide 5 to 7.5 mg weekly
• Refill consistency: very high (>90% on-time refills), because missing doses causes immediate glucose elevation
• Side-effect tolerance: higher, because the alternative (uncontrolled diabetes) has worse long-term consequences

Profile 2: Weight-management-primary patients (approximately 65% of compounded GLP-1 patients in our network)

• A1C at baseline: 5.0% to 6.2% (normal or pre-diabetic)
• BMI at baseline: 30 to 42
• Primary goal: weight loss
• Secondary goal: metabolic health improvement (lipids, blood pressure, inflammatory markers)
• Typical maintenance dose: semaglutide 1.7 to 2.4 mg weekly, or tirzepatide 10 to 15 mg weekly
• Refill consistency: moderate (70-80% on-time refills), with more dose interruptions due to side effects or cost
• Side-effect tolerance: lower, because the alternative (remaining at current weight) does not cause immediate symptoms

The pattern reveals that diabetes patients and weight-management patients have different risk-benefit calculations, different dose requirements, and different adherence patterns. The original FDA approval (diabetes) and the later approval (weight management) reflect genuinely different clinical populations, not just regulatory categories.

The dose difference is the clearest signal. Diabetes-primary patients rarely escalate beyond 1 mg semaglutide because their A1C reaches target (<7%) at that dose. Weight-management-primary patients frequently escalate to 2 to 2.4 mg because weight loss is dose-dependent and their goal is typically 10% to 15% total body weight reduction, which requires higher doses.

The observation that matters: treating these as the same patient population with the same drug is a category error. The original purpose (diabetes) and the expanded purpose (weight management) require different dosing strategies, different monitoring, and different shared decision-making about risks and benefits.

When off-label use is appropriate and when it is not

Off-label prescribing is legal, common, and often medically appropriate. An estimated 20% of all prescriptions in the U.S. are for off-label uses. The FDA approves drugs for specific indications based on clinical trial evidence, but prescribers are allowed to use clinical judgment to prescribe approved drugs for other conditions.

When off-label Ozempic for weight management is appropriate:

1. The patient has pre-diabetes (A1C 5.7% to 6.4%) and obesity. The patient is at high risk of progressing to type 2 diabetes, and weight loss reduces that risk. Ozempic addresses both the glucose and weight components.

1. The patient has tried Wegovy but cannot tolerate the 2.4 mg dose. Some patients have better side-effect profiles at 1 to 1.7 mg. Ozempic allows dose customization that Wegovy pens do not.

1. Wegovy is unavailable or not covered by insurance, and the patient has weight-related comorbidities (hypertension, sleep apnea, fatty liver disease, osteoarthritis). The clinical benefit of weight loss outweighs the appropriateness concern.

1. The patient is transitioning from Ozempic (started for diabetes) to weight maintenance after A1C normalizes. Some patients start Ozempic for diabetes, lose enough weight that their A1C normalizes and they no longer meet diabetes criteria, but continuing the medication prevents weight regain.

When off-label Ozempic for weight management is not appropriate:

1. Wegovy is available and covered by the patient's insurance. There is no clinical reason to prescribe the diabetes-indicated product when the weight-management-indicated product is accessible.

1. The patient does not have obesity or weight-related comorbidities. Prescribing GLP-1 agonists for cosmetic weight loss in patients with BMI <27 and no comorbidities is outside evidence-based guidelines.

1. The prescription is written primarily to circumvent insurance non-coverage of weight-loss drugs. While understandable, this practice contributed to the supply crisis that harmed diabetes patients.

1. The patient has not tried lifestyle modification or other first-line weight-management interventions. GLP-1 agonists are adjuncts to diet and exercise, not replacements.

The ethical tension is real. Insurers often deny coverage for weight-loss medications while covering diabetes medications, even though obesity is a recognized chronic disease. Prescribers face a choice: prescribe off-label to help patients access effective treatment, or adhere strictly to indications and watch patients go untreated.

The better solution is policy change: insurers should cover evidence-based weight-management medications the same way they cover diabetes medications. Until that happens, off-label prescribing will continue, and the appropriateness question will remain contested.

FAQ

What was Ozempic originally approved for? Ozempic was approved by the FDA in December 2017 for improving blood sugar control in adults with type 2 diabetes. It was not approved for weight loss. The approval was based on clinical trials showing A1C reduction and cardiovascular benefit in diabetic patients.

Is Ozempic approved for weight loss? No. Ozempic is only FDA-approved for type 2 diabetes. The same active ingredient (semaglutide) is approved for weight management under the brand name Wegovy at a higher dose (2.4 mg weekly). Prescribing Ozempic for weight loss is off-label use.

When did Ozempic get approved? Ozempic received FDA approval on December 5, 2017. The initial approved doses were 0.5 mg and 1 mg once weekly. A 2 mg dose was added in January 2020.

What is the difference between Ozempic and Wegovy? Both contain semaglutide, but Ozempic is approved for type 2 diabetes (max dose 2 mg weekly) and Wegovy is approved for weight management (standard dose 2.4 mg weekly). They have different pen devices, different dosing schedules, and different FDA indications. Insurance coverage differs significantly between the two.

Why do doctors prescribe Ozempic for weight loss if it is not approved for that? Doctors prescribe Ozempic off-label for weight loss because it is effective, often better covered by insurance than Wegovy, and was more consistently available during the 2022-2023 Wegovy shortage. Off-label prescribing is legal and common in U.S. medical practice.

Can I take Ozempic if I do not have diabetes? Legally, yes, if a licensed provider prescribes it. Clinically, the question is whether the benefits outweigh the risks. If you have obesity or overweight with weight-related health conditions, off-label Ozempic may be appropriate. If you are seeking cosmetic weight loss without medical need, it is not appropriate.

What were the original Ozempic clinical trials? The SUSTAIN trial program (SUSTAIN-1 through SUSTAIN-10) tested semaglutide in over 8,000 patients with type 2 diabetes. The trials showed A1C reductions of 1.5% to 1.8% and weight loss of 4 to 6 kg on average. SUSTAIN-6 showed a 26% reduction in cardiovascular events compared to placebo.

How much weight do people lose on Ozempic? In diabetes trials, patients lost an average of 4 to 6 kg (9 to 13 pounds) over 6 to 12 months. In weight-management trials using the higher Wegovy dose, patients lost an average of 15% of body weight over 68 weeks. Weight loss on Ozempic at diabetes doses is typically less than on Wegovy.

Is compounded semaglutide the same as Ozempic? No. Compounded semaglutide is prepared by a compounding pharmacy and is not FDA-approved. It contains the same active ingredient but has not undergone the same testing, quality control, or regulatory review as brand-name Ozempic. Compounded versions are legal under FDA guidelines during drug shortages.

Why was there an Ozempic shortage? The shortage in 2022-2023 was caused by a combination of manufacturing capacity limits, higher-than-expected demand for diabetes treatment, and a surge in off-label prescribing for weight loss. Novo Nordisk expanded production capacity, and supply stabilized by late 2023.

Did Novo Nordisk know Ozempic would cause weight loss? Yes. Earlier GLP-1 drugs had already shown weight-loss effects, and Novo Nordisk's own liraglutide product was approved for weight management (as Saxenda) in 2014. The weight-loss effect was expected and documented in all SUSTAIN trials, but the FDA approval focused on glucose control because that was the primary endpoint.

What conditions is Ozempic approved to treat? Ozempic is approved only for type 2 diabetes in adults. It is also approved to reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease. It is not approved for type 1 diabetes, weight loss, or any other condition.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Frías JP et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021.
5. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinology. 2017.
6. Ahrén B et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients with Type 2 Diabetes (SUSTAIN 2): A 56-Week, Double-Blind, Phase 3a, Randomised Trial. Lancet Diabetes Endocrinology. 2017.
7. Ahmann AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018.
8. Aroda VR et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin (With or Without Sulfonylureas) in Insulin-Naive Patients with Type 2 Diabetes (SUSTAIN 4): A Randomised, Open-Label, Parallel-Group, Multicentre, Multinational, Phase 3a Trial. Lancet Diabetes Endocrinology. 2017.
9. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinology. 2018.
10. FDA approval letter for Ozempic (semaglutide injection). December 5, 2017.
11. FDA approval letter for Wegovy (semaglutide injection). June 4, 2021.
12. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
13. American Diabetes Association. Statement on GLP-1 Receptor Agonist Shortages. August 2022.
14. Iqvia Institute. Use of GLP-1 Receptor Agonists in the U.S.: Trends in Prescribing Patterns 2018-2023. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical company.